Skip to main content
S&P 5007,683.11+1.51%DOW53,335.29+2.99%NASDAQ25,714.14+1.35%BTC$80,010.00+2.84%ETH$2,411.88+5.33%GOLD$4,071.00+3.31%OIL$88.69-7.70%
Smart Investors Daily
SID Premium
SE

NYSE · SER

Serina Therapeutics, Inc.

Healthcare · Biotechnology

$1.83

Down-$0.19 (-10.33%)

Updated Nov 4, 2026, 8:52 PM

SID Score

4.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
33.49M
P/E ratio
-2.49
Dividend yield
0.00%
52-week range
$1.22 – $3.29
Volume
30.59K
Avg. volume
27.05K

Price performance · SER

SER price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 3, 2026

SER closed at $1.83 after 21 trading sessions, down 10.29% for the selected period.

Last close
$1.83
Period change
-10.29%
Period low
$1.64
Period high
$2.04
Daily close
View OHLC price history
SER OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 3, 2026$1.79$1.85$1.67$1.8330.59K
Nov 2, 2026$1.92$2.00$1.85$1.8538.99K
Oct 30, 2026$1.47$2.55$1.47$1.94155.11K
Oct 29, 2026$1.51$1.99$1.46$1.8966.35K
Oct 28, 2026$1.28$1.70$1.28$1.6428.26K
Oct 27, 2026$1.38$1.80$1.38$1.67172.03K
Oct 26, 2026$1.63$1.7499$1.5879$1.7138.29K
Oct 23, 2026$1.73$1.76$1.65$1.658K
Oct 22, 2026$1.73$1.80$1.72$1.7651.26K
Oct 21, 2026$1.67$1.78$1.63$1.7739.79K
Oct 20, 2026$1.64$1.735$1.63$1.6642.13K
Oct 19, 2026$1.75$1.81$1.65$1.6522.06K
Oct 16, 2026$1.72$1.83$1.72$1.7215.67K
Oct 15, 2026$1.71$1.94$1.71$1.7927.44K
Oct 14, 2026$1.80$1.8376$1.71$1.7146.26K
Oct 13, 2026$1.92$1.9737$1.7801$1.8226.33K
Oct 12, 2026$2.01$2.01$1.90$1.94132.24K
Oct 9, 2026$1.99$2.05$1.99$2.0022.35K
Oct 8, 2026$2.01$2.05$1.99$2.0159.29K
Oct 7, 2026$2.04$2.08$2.01$2.0113.18K
Oct 6, 2026$2.025$2.0796$2.0162$2.048.72K

Latest SER news

The latest Smart Investors Daily articles mentioning SER.

Stock researchCompany · Overview

SER research

Overview

Company profile and research snapshot.

Company profile

Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
SER recent ratings
DateFirmRatingTarget
Oct 26, 2026BTIGBuy—
Sep 10, 2026BTIGBuy—
Jul 1, 2026BTIGBuy—
Aug 28, 2025HC Wainwright & Co.Buy—
Jul 14, 2025HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Jul 24, 2026

Serina Therapeutics to Participate in the BTIG Virtual Biotechnology Conference

HUNTSVILLE, Ala., July 24, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the “Company”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced that management will participate in the BTIG Virtual Biotechnology Conference, taking place July 28-29, 2026. Management will hold virtual one-on-one investor meetings on Wednesday, July 29, 2026. Please contact your BTIG representative to reques

Yahoo · Jul 23, 2026

Serina Therapeutics Announces Completion of Enrollment and Dosing in Cohort 1 of Registrational Trial of SER-252 for Advanced Parkinson’s Disease

- All eight patients enrolled and dosed in Cohort 1 ahead of previously disclosed guidance of the end of the third quarter of 2026 - - Independent Safety Monitoring Committee to review Cohort 1 safety and tolerability in accordance with the study protocol - - Company expects to provide a further update following completion of the Safety Monitoring Committee review – HUNTSVILLE, Ala., July 23, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a c

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By